Rethinking Commercial Viability in CGT with Treehill Partners’ Ali Pashazadeh
From Cell & Gene: The Podcast · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1810482/fan_mail/new)
Episode 141 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Ali Pashazadeh, Founder, Chairman, and CEO of Treehill Partners, about the manufacturing challenges that continue to limit cell and gene therapy development. They explore why manufacturing feasibility, scale-up, and cost efficiency must be addressed early, how developers should approach CDMO partnerships, why operational planning must connect preclinical development through commercialization, and more.
Subscribe to the podcast! Apple (https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063) | Spotify (https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya) | YouTube (https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX)
Visit my website: Cell & Gene (https://www.cellandgene.com/)
Connect with me on LinkedIn (https://www.linkedin.com/in/erinharris/)